Loading asset research
Q3 2026 earnings · Nov 5
Replimune Group Inc. Common Stock
REPLNasdaq · USD · StocksQuote as of · Exchange session not verified$12.36
-4.63%
Today
REPL
Loading 1D prices…
Market cap
$1.2B
Volume
2.6M
52w high
$16.3352w low
$1.50Company profile
Replimune Group Inc. Common Stock
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.
Sector
Health Care
Industry
Biological Products, (No Diagnostic Substances)
Exchange
Nasdaq
Display currency
USD
Location
Woburn, MA, United States
Employees
465
Fiscal year end
0331
CIK
1737953
Session & valuation
Open$12.87
Previous close$12.96
Day high$12.88
Day low$12.07
30-day avg. volume2.5M
Outstanding shares94.2M
Diluted EPS-$3.38
Latest annual period
P/E (trailing)-3.66
P/E (forward)-6.18
Price / book10.02
Beta0.94
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2836
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| IMTXImmatics N.V. Ordinary Shares | $1.3B | — | — | -$1.61 | -2.21% | Buy |
| MGTXMeiraGTx Holdings plc Ordinary Shares | $1.1B | $81.4M | -140.31% | -$1.42 | -7.32% | Buy |
| GLUEMonte Rosa Therapeutics Inc. Common Stock | $999.9M | $123.7M | -31.21% | -$0.5893 | -1.85% | Buy |
| VORVor Biopharma Inc. Common Stock | $999.2M | $0.00 | — | -$70.50 | -4.80% | Buy |
| CGEMCullinan Therapeutics Inc. Common Stock | $993.6M | $0.00 | — | -$3.36 | -10.67% | Buy |